Search

Your search keyword '"Leyvraz, Serge"' showing total 454 results
Start Over Author "Leyvraz, Serge"
454 results on '"Leyvraz, Serge"'

1. A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma

Author

Sacco, Joseph J., Jackson, Richard, Corrie, Pippa, Danson, Sarah, Evans, T.R. Jeffry, Ochsenreither, Sebastian, Kumar, Satish, Goodman, Andrew, Larkin, James, Karydis, Ioannis, Steven, Neil, Lorigan, Paul, Plummer, Ruth, Patel, Poulam, Psarelli, Eftychia, Olsson-Brown, Anna, Shaw, Heather, Leyvraz, Serge, Handley, Louise, Rawcliffe, Charlotte, and Nathan, Paul

Published
2024
Full Text
View/download PDF

3. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial

Author

Carvajal, Richard D., Butler, Marcus O., Shoushtari, Alexander N., Hassel, Jessica C., Ikeguchi, Alexandra, Hernandez-Aya, Leonel, Nathan, Paul, Hamid, Omid, Piulats, Josep M., Rioth, Matthew, Johnson, Douglas B., Luke, Jason J., Espinosa, Enrique, Leyvraz, Serge, Collins, Laura, Goodall, Howard M., Ranade, Koustubh, Holland, Chris, Abdullah, Shaad E., Sacco, Joseph J., and Sato, Takami

Published
2022
Full Text
View/download PDF

4. Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma

Author

Sacco, Joseph J, primary, Carvajal, Richard D, additional, Butler, Marcus O, additional, Shoushtari, Alexander N, additional, Hassel, Jessica C, additional, Ikeguchi, Alexandra, additional, Hernandez-Aya, Leonel, additional, Nathan, Paul, additional, Hamid, Omid, additional, Piulats, Josep M, additional, Rioth, Matthew, additional, Johnson, Douglas B, additional, Luke, Jason J, additional, Espinosa, Enrique, additional, Leyvraz, Serge, additional, Collins, Laura, additional, Holland, Chris, additional, and Sato, Takami, additional

Published
2024
Full Text
View/download PDF

6. Updated efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion gastrointestinal (GI) cancer.

Author

Shen, Lin, primary, Andre, Thierry, additional, Chung, Hyun Cheol Cheol, additional, Deeken, John F., additional, Garralda, Elena, additional, Italiano, Antoine, additional, Leyvraz, Serge, additional, Liu, Tianshu, additional, Burcoveanu, Domnita-Ileana, additional, Grugel, Robin, additional, Mussi, Chiara E., additional, Xu, Rui-Hua, additional, Hong, David S., additional, Drilon, Alexander E., additional, and Berlin, Jordan, additional

Published
2024
Full Text
View/download PDF

8. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas

Author

Kummar, Shivaani, primary, Shen, Lin, additional, Hong, David S., additional, McDermott, Ray, additional, Keedy, Vicki L., additional, Casanova, Michela, additional, Demetri, George D., additional, Dowlati, Afshin, additional, Melcón, Soledad Gallego, additional, Lassen, Ulrik N., additional, Leyvraz, Serge, additional, Liu, Tianshu, additional, Moreno, Victor, additional, Patel, Jyoti, additional, Patil, Tejas, additional, Mallick, Atrayee Basu, additional, Sousa, Nuno, additional, Tahara, Makoto, additional, Ziegler, David S., additional, Norenberg, Ricarda, additional, Arvis, Pierre, additional, Brega, Nicoletta, additional, Drilon, Alexander, additional, and Tan, Daniel S. W., additional

Published
2023
Full Text
View/download PDF

9. TABLE 1 from A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors

Author

Hanna, Glenn J., primary, Stathis, Anastasios, primary, Lopez-Miranda, Elena, primary, Racca, Fabricio, primary, Quon, Doris, primary, Leyvraz, Serge, primary, Hess, Dagmar, primary, Keam, Bhumsuk, primary, Rodon, Jordi, primary, Ahn, Myung-Ju, primary, Kim, Hye Ryun, primary, Schneeweiss, Andreas, primary, Ribera, Josep-Maria, primary, DeAngelo, Daniel, primary, Perez Garcia, Jose Manuel, primary, Cortes, Javier, primary, Schönborn-Kellenberger, Oliver, primary, Weber, Dirk, primary, Pisa, Pavel, primary, Bauer, Michael, primary, Beni, Laura, primary, Bobadilla, Maria, primary, Lehal, Raj, primary, Vigolo, Michele, primary, Vogl, Florian D., primary, and Garralda, Elena, primary

Published
2023
Full Text
View/download PDF

10. TABLE 2 from A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors

Author

Hanna, Glenn J., primary, Stathis, Anastasios, primary, Lopez-Miranda, Elena, primary, Racca, Fabricio, primary, Quon, Doris, primary, Leyvraz, Serge, primary, Hess, Dagmar, primary, Keam, Bhumsuk, primary, Rodon, Jordi, primary, Ahn, Myung-Ju, primary, Kim, Hye Ryun, primary, Schneeweiss, Andreas, primary, Ribera, Josep-Maria, primary, DeAngelo, Daniel, primary, Perez Garcia, Jose Manuel, primary, Cortes, Javier, primary, Schönborn-Kellenberger, Oliver, primary, Weber, Dirk, primary, Pisa, Pavel, primary, Bauer, Michael, primary, Beni, Laura, primary, Bobadilla, Maria, primary, Lehal, Raj, primary, Vigolo, Michele, primary, Vogl, Florian D., primary, and Garralda, Elena, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Table 3 from A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors

Author

Hanna, Glenn J., primary, Stathis, Anastasios, primary, Lopez-Miranda, Elena, primary, Racca, Fabricio, primary, Quon, Doris, primary, Leyvraz, Serge, primary, Hess, Dagmar, primary, Keam, Bhumsuk, primary, Rodon, Jordi, primary, Ahn, Myung-Ju, primary, Kim, Hye Ryun, primary, Schneeweiss, Andreas, primary, Ribera, Josep-Maria, primary, DeAngelo, Daniel, primary, Perez Garcia, Jose Manuel, primary, Cortes, Javier, primary, Schönborn-Kellenberger, Oliver, primary, Weber, Dirk, primary, Pisa, Pavel, primary, Bauer, Michael, primary, Beni, Laura, primary, Bobadilla, Maria, primary, Lehal, Raj, primary, Vigolo, Michele, primary, Vogl, Florian D., primary, and Garralda, Elena, primary

Published
2023
Full Text
View/download PDF

12. Data from A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors

Author

Hanna, Glenn J., primary, Stathis, Anastasios, primary, Lopez-Miranda, Elena, primary, Racca, Fabricio, primary, Quon, Doris, primary, Leyvraz, Serge, primary, Hess, Dagmar, primary, Keam, Bhumsuk, primary, Rodon, Jordi, primary, Ahn, Myung-Ju, primary, Kim, Hye Ryun, primary, Schneeweiss, Andreas, primary, Ribera, Josep-Maria, primary, DeAngelo, Daniel, primary, Perez Garcia, Jose Manuel, primary, Cortes, Javier, primary, Schönborn-Kellenberger, Oliver, primary, Weber, Dirk, primary, Pisa, Pavel, primary, Bauer, Michael, primary, Beni, Laura, primary, Bobadilla, Maria, primary, Lehal, Raj, primary, Vigolo, Michele, primary, Vogl, Florian D., primary, and Garralda, Elena, primary

Published
2023
Full Text
View/download PDF

13. FIGURE 1 from A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors

Author

Hanna, Glenn J., primary, Stathis, Anastasios, primary, Lopez-Miranda, Elena, primary, Racca, Fabricio, primary, Quon, Doris, primary, Leyvraz, Serge, primary, Hess, Dagmar, primary, Keam, Bhumsuk, primary, Rodon, Jordi, primary, Ahn, Myung-Ju, primary, Kim, Hye Ryun, primary, Schneeweiss, Andreas, primary, Ribera, Josep-Maria, primary, DeAngelo, Daniel, primary, Perez Garcia, Jose Manuel, primary, Cortes, Javier, primary, Schönborn-Kellenberger, Oliver, primary, Weber, Dirk, primary, Pisa, Pavel, primary, Bauer, Michael, primary, Beni, Laura, primary, Bobadilla, Maria, primary, Lehal, Raj, primary, Vigolo, Michele, primary, Vogl, Florian D., primary, and Garralda, Elena, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Table 1 from A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors

Author

Hanna, Glenn J., primary, Stathis, Anastasios, primary, Lopez-Miranda, Elena, primary, Racca, Fabricio, primary, Quon, Doris, primary, Leyvraz, Serge, primary, Hess, Dagmar, primary, Keam, Bhumsuk, primary, Rodon, Jordi, primary, Ahn, Myung-Ju, primary, Kim, Hye Ryun, primary, Schneeweiss, Andreas, primary, Ribera, Josep-Maria, primary, DeAngelo, Daniel, primary, Perez Garcia, Jose Manuel, primary, Cortes, Javier, primary, Schönborn-Kellenberger, Oliver, primary, Weber, Dirk, primary, Pisa, Pavel, primary, Bauer, Michael, primary, Beni, Laura, primary, Bobadilla, Maria, primary, Lehal, Raj, primary, Vigolo, Michele, primary, Vogl, Florian D., primary, and Garralda, Elena, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Table 4 from A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors

Author

Hanna, Glenn J., primary, Stathis, Anastasios, primary, Lopez-Miranda, Elena, primary, Racca, Fabricio, primary, Quon, Doris, primary, Leyvraz, Serge, primary, Hess, Dagmar, primary, Keam, Bhumsuk, primary, Rodon, Jordi, primary, Ahn, Myung-Ju, primary, Kim, Hye Ryun, primary, Schneeweiss, Andreas, primary, Ribera, Josep-Maria, primary, DeAngelo, Daniel, primary, Perez Garcia, Jose Manuel, primary, Cortes, Javier, primary, Schönborn-Kellenberger, Oliver, primary, Weber, Dirk, primary, Pisa, Pavel, primary, Bauer, Michael, primary, Beni, Laura, primary, Bobadilla, Maria, primary, Lehal, Raj, primary, Vigolo, Michele, primary, Vogl, Florian D., primary, and Garralda, Elena, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 1 from A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors

Author

Hanna, Glenn J., primary, Stathis, Anastasios, primary, Lopez-Miranda, Elena, primary, Racca, Fabricio, primary, Quon, Doris, primary, Leyvraz, Serge, primary, Hess, Dagmar, primary, Keam, Bhumsuk, primary, Rodon, Jordi, primary, Ahn, Myung-Ju, primary, Kim, Hye Ryun, primary, Schneeweiss, Andreas, primary, Ribera, Josep-Maria, primary, DeAngelo, Daniel, primary, Perez Garcia, Jose Manuel, primary, Cortes, Javier, primary, Schönborn-Kellenberger, Oliver, primary, Weber, Dirk, primary, Pisa, Pavel, primary, Bauer, Michael, primary, Beni, Laura, primary, Bobadilla, Maria, primary, Lehal, Raj, primary, Vigolo, Michele, primary, Vogl, Florian D., primary, and Garralda, Elena, primary

Published
2023
Full Text
View/download PDF

17. TABLE 3 from A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors

Author

Hanna, Glenn J., primary, Stathis, Anastasios, primary, Lopez-Miranda, Elena, primary, Racca, Fabricio, primary, Quon, Doris, primary, Leyvraz, Serge, primary, Hess, Dagmar, primary, Keam, Bhumsuk, primary, Rodon, Jordi, primary, Ahn, Myung-Ju, primary, Kim, Hye Ryun, primary, Schneeweiss, Andreas, primary, Ribera, Josep-Maria, primary, DeAngelo, Daniel, primary, Perez Garcia, Jose Manuel, primary, Cortes, Javier, primary, Schönborn-Kellenberger, Oliver, primary, Weber, Dirk, primary, Pisa, Pavel, primary, Bauer, Michael, primary, Beni, Laura, primary, Bobadilla, Maria, primary, Lehal, Raj, primary, Vigolo, Michele, primary, Vogl, Florian D., primary, and Garralda, Elena, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 2 from A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors

Author

Hanna, Glenn J., primary, Stathis, Anastasios, primary, Lopez-Miranda, Elena, primary, Racca, Fabricio, primary, Quon, Doris, primary, Leyvraz, Serge, primary, Hess, Dagmar, primary, Keam, Bhumsuk, primary, Rodon, Jordi, primary, Ahn, Myung-Ju, primary, Kim, Hye Ryun, primary, Schneeweiss, Andreas, primary, Ribera, Josep-Maria, primary, DeAngelo, Daniel, primary, Perez Garcia, Jose Manuel, primary, Cortes, Javier, primary, Schönborn-Kellenberger, Oliver, primary, Weber, Dirk, primary, Pisa, Pavel, primary, Bauer, Michael, primary, Beni, Laura, primary, Bobadilla, Maria, primary, Lehal, Raj, primary, Vigolo, Michele, primary, Vogl, Florian D., primary, and Garralda, Elena, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 3 from A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors

Author

Hanna, Glenn J., primary, Stathis, Anastasios, primary, Lopez-Miranda, Elena, primary, Racca, Fabricio, primary, Quon, Doris, primary, Leyvraz, Serge, primary, Hess, Dagmar, primary, Keam, Bhumsuk, primary, Rodon, Jordi, primary, Ahn, Myung-Ju, primary, Kim, Hye Ryun, primary, Schneeweiss, Andreas, primary, Ribera, Josep-Maria, primary, DeAngelo, Daniel, primary, Perez Garcia, Jose Manuel, primary, Cortes, Javier, primary, Schönborn-Kellenberger, Oliver, primary, Weber, Dirk, primary, Pisa, Pavel, primary, Bauer, Michael, primary, Beni, Laura, primary, Bobadilla, Maria, primary, Lehal, Raj, primary, Vigolo, Michele, primary, Vogl, Florian D., primary, and Garralda, Elena, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Table 2 from A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors

Author

Hanna, Glenn J., primary, Stathis, Anastasios, primary, Lopez-Miranda, Elena, primary, Racca, Fabricio, primary, Quon, Doris, primary, Leyvraz, Serge, primary, Hess, Dagmar, primary, Keam, Bhumsuk, primary, Rodon, Jordi, primary, Ahn, Myung-Ju, primary, Kim, Hye Ryun, primary, Schneeweiss, Andreas, primary, Ribera, Josep-Maria, primary, DeAngelo, Daniel, primary, Perez Garcia, Jose Manuel, primary, Cortes, Javier, primary, Schönborn-Kellenberger, Oliver, primary, Weber, Dirk, primary, Pisa, Pavel, primary, Bauer, Michael, primary, Beni, Laura, primary, Bobadilla, Maria, primary, Lehal, Raj, primary, Vigolo, Michele, primary, Vogl, Florian D., primary, and Garralda, Elena, primary

Published
2023
Full Text
View/download PDF

21. FIGURE 2 from A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors

Author

Hanna, Glenn J., primary, Stathis, Anastasios, primary, Lopez-Miranda, Elena, primary, Racca, Fabricio, primary, Quon, Doris, primary, Leyvraz, Serge, primary, Hess, Dagmar, primary, Keam, Bhumsuk, primary, Rodon, Jordi, primary, Ahn, Myung-Ju, primary, Kim, Hye Ryun, primary, Schneeweiss, Andreas, primary, Ribera, Josep-Maria, primary, DeAngelo, Daniel, primary, Perez Garcia, Jose Manuel, primary, Cortes, Javier, primary, Schönborn-Kellenberger, Oliver, primary, Weber, Dirk, primary, Pisa, Pavel, primary, Bauer, Michael, primary, Beni, Laura, primary, Bobadilla, Maria, primary, Lehal, Raj, primary, Vigolo, Michele, primary, Vogl, Florian D., primary, and Garralda, Elena, primary

Published
2023
Full Text
View/download PDF

22. A phase 1 study of the pan-Notch inhibitor CB-103 for patients with advanced adenoid cystic carcinoma and other tumors

Author

Hanna, Glenn J., primary, Stathis, Anastasios, additional, Lopez-Miranda, Elena, additional, Racca, Fabricio, additional, Quon, Doris, additional, Leyvraz, Serge, additional, Hess, Dagmar, additional, Keam, Bhumsuk, additional, Rodon, Jordi, additional, Ahn, Myung-Ju, additional, Kim, Hye Ryun, additional, Schneeweiss, Andreas, additional, Ribera, Josep-Maria, additional, DeAngelo, Daniel, additional, Perez-Garcia, Jose Manuel, additional, Cortes, Javier, additional, Schönborn-Kellenberger, Oliver, additional, Weber, Dirk, additional, Pisa, Pavel, additional, Bauer, Michael, additional, Beni, Laura, additional, Bobadilla, Maria, additional, Lehal, Raj, additional, Vigolo, Michele, additional, Vogl, Florian D., additional, and Garralda, Elena, additional

Published
2023
Full Text
View/download PDF

23. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma

Author

Pertesi, Maroulio, Vallée, Maxime, Wei, Xiaomu, Revuelta, Maria V., Galia, Perrine, Demangel, Delphine, Oliver, Javier, Foll, Matthieu, Chen, Siwei, Perrial, Emeline, Garderet, Laurent, Corre, Jill, Leleu, Xavier, Boyle, Eileen M., Decaux, Olivier, Rodon, Philippe, Kolb, Brigitte, Slama, Borhane, Mineur, Philippe, Voog, Eric, Le Bris, Catherine, Fontan, Jean, Maigre, Michel, Beaumont, Marie, Azais, Isabelle, Sobol, Hagay, Vignon, Marguerite, Royer, Bruno, Perrot, Aurore, Fuzibet, Jean-Gabriel, Dorvaux, Véronique, Anglaret, Bruno, Cony-Makhoul, Pascale, Berthou, Christian, Desquesnes, Florence, Pegourie, Brigitte, Leyvraz, Serge, Mosser, Laurent, Frenkiel, Nicole, Augeul-Meunier, Karine, Leduc, Isabelle, Leyronnas, Cécile, Voillat, Laurent, Casassus, Philippe, Mathiot, Claire, Cheron, Nathalie, Paubelle, Etienne, Moreau, Philippe, Bignon, Yves–Jean, Joly, Bertrand, Bourquard, Pascal, Caillot, Denis, Naman, Hervé, Rigaudeau, Sophie, Marit, Gérald, Macro, Margaret, Lambrecht, Isabelle, Cliquennois, Manuel, Vincent, Laure, Helias, Philippe, Avet-Loiseau, Hervé, Moreno, Victor, Reis, Rui Manuel, Varkonyi, Judit, Kruszewski, Marcin, Vangsted, Annette Juul, Jurczyszyn, Artur, Zaucha, Jan Maciej, Sainz, Juan, Krawczyk-Kulis, Malgorzata, Wątek, Marzena, Pelosini, Matteo, Iskierka-Jażdżewska, Elzbieta, Grząśko, Norbert, Martinez-Lopez, Joaquin, Jerez, Andrés, Campa, Daniele, Buda, Gabriele, Lesueur, Fabienne, Dudziński, Marek, García-Sanz, Ramón, Nagler, Arnon, Rymko, Marcin, Jamroziak, Krzysztof, Butrym, Aleksandra, Canzian, Federico, Obazee, Ofure, Nilsson, Björn, Klein, Robert J., Lipkin, Steven M., McKay, James D., and Dumontet, Charles

Published
2019
Full Text
View/download PDF

24. Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC).

Author

Cabanillas, Maria E., primary, Lin, Jessica Jiyeong, additional, Brose, Marcia S., additional, McDermott, Raymond S., additional, Almubarak, Mohammed, additional, Bauman, Jessica R, additional, Casanova, Michela, additional, Kummar, Shivaani, additional, Lee, Se-Hoon, additional, Leyvraz, Serge, additional, Oh, Do-Youn, additional, Shen, Lin, additional, Norenberg, Ricarda, additional, Bernard-Gauthier, Vadim, additional, Mussi, Chiara E., additional, Hong, David S., additional, Drilon, Alexander E., additional, and Waguespack, Steven G., additional

Published
2023
Full Text
View/download PDF

26. Abstract CT223: Long-term survival follow-up of tebentafusp in previously treated metastatic uveal melanoma (mUM)

Author

Sacco, Joseph J., primary, Carvajal, Richard D., additional, Butler, Marcus O., additional, Shoushtari, Alexander N., additional, Hassel, Jessica C., additional, Ikeguchi, Alexandra, additional, Hernandez-Aya, Leonel, additional, Nathan, Paul, additional, Hamid, Omid, additional, Piulats, Josep M., additional, Rioth, Matthew, additional, Johnson, Douglas B., additional, Luke, Jason J., additional, Espinosa, Erique, additional, Leyvraz, Serge, additional, Collins, Laura, additional, Holland, Chris, additional, McCully, Michelle L., additional, and Sato, Takami, additional

Published
2023
Full Text
View/download PDF

27. Supplementary Figure 1 from Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era

Author

Cassier, Philippe A., primary, Fumagalli, Elena, primary, Rutkowski, Piotr, primary, Schöffski, Patrick, primary, Van Glabbeke, Martine, primary, Debiec-Rychter, Maria, primary, Emile, Jean-François, primary, Duffaud, Florence, primary, Martin-Broto, Javier, primary, Landi, Bruno, primary, Adenis, Antoine, primary, Bertucci, François, primary, Bompas, Emmanuelle, primary, Bouché, Olivier, primary, Leyvraz, Serge, primary, Judson, Ian, primary, Verweij, Jaap, primary, Casali, Paolo, primary, Blay, Jean-Yves, primary, and Hohenberger, Peter, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Tables 1-3, Figures 1-4, Investigator List from Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure

Author

Demetri, George D., primary, Garrett, Christopher R., primary, Schöffski, Patrick, primary, Shah, Manisha H., primary, Verweij, Jaap, primary, Leyvraz, Serge, primary, Hurwitz, Herbert I., primary, Pousa, Antonio Lopez, primary, Le Cesne, Axel, primary, Goldstein, David, primary, Paz-Ares, Luis, primary, Blay, Jean-Yves, primary, McArthur, Grant A., primary, Xu, Qiang (Casey), primary, Huang, Xin, primary, Harmon, Charles S., primary, Tassell, Vanessa, primary, Cohen, Darrel P., primary, and Casali, Paolo G., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure 2 from Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era

Author

Cassier, Philippe A., primary, Fumagalli, Elena, primary, Rutkowski, Piotr, primary, Schöffski, Patrick, primary, Van Glabbeke, Martine, primary, Debiec-Rychter, Maria, primary, Emile, Jean-François, primary, Duffaud, Florence, primary, Martin-Broto, Javier, primary, Landi, Bruno, primary, Adenis, Antoine, primary, Bertucci, François, primary, Bompas, Emmanuelle, primary, Bouché, Olivier, primary, Leyvraz, Serge, primary, Judson, Ian, primary, Verweij, Jaap, primary, Casali, Paolo, primary, Blay, Jean-Yves, primary, and Hohenberger, Peter, primary

Published
2023
Full Text
View/download PDF

30. Induktionstherapie bei Sarkomen

Author

Matter, Maurice, Gay, Beatrice, Christinat, Alexandre, Zouhair, Abderrahim, Leyvraz, Serge, Aigner, Karl Reinhard, editor, Stephens, Frederick O., editor, Vogl, Thomas J., editor, and Padberg, Winfried, editor

Published
2013
Full Text
View/download PDF

31. Induction Treatment in Sarcomas

Author

Matter, Maurice, Gay, Beatrice, Christinat, Alexandre, Zouhair, Abderrahim, Leyvraz, Serge, Aigner, Karl Reinhard, editor, and Stephens, Frederick O., editor

Published
2011
Full Text
View/download PDF

32. Biomarker-driven therapies for metastatic uveal melanoma: A prospective precision oncology feasibility study

Author

Leyvraz, Serge, primary, Konietschke, Frank, additional, Peuker, Caroline, additional, Schütte, Moritz, additional, Kessler, Thomas, additional, Ochsenreither, Sebastian, additional, Ditzhaus, Marc, additional, Sprünken, Erin D., additional, Dörpholz, Gina, additional, Lamping, Mario, additional, Rieke, Damian T., additional, Klinghammer, Konrad, additional, Burock, Susen, additional, Ulrich, Claas, additional, Poch, Gabriela, additional, Schäfer, Reinhold, additional, Klauschen, Frederick, additional, Joussen, Antonia, additional, Yaspo, Marie-Laure, additional, and Keilholz, Ulrich, additional

Published
2022
Full Text
View/download PDF

33. Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer.

Author

Drilon, Alexander E., primary, Lin, Jessica Jiyeong, additional, Kummar, Shivaani, additional, Tan, Daniel Shao-Weng, additional, Patel, Jyoti D., additional, Lassen, Ulrik Niels, additional, Leyvraz, Serge, additional, Moreno, Victor, additional, Rosen, Lee S., additional, Solomon, Benjamin Maurice, additional, Yachnin, Jeffrey, additional, Liu, Yongmei, additional, Dai, Ming-Shen, additional, Norenberg, Ricarda, additional, Fellous, Marc Mardoche, additional, Mussi, Chiara Erminia, additional, and Shen, Lin, additional

Published
2022
Full Text
View/download PDF

34. First interim analysis of the SirTac trial: A randomized phase II study of SIRT and DSM-TACE in patients with liver metastases from uveal melanoma.

Author

Peuker, Caroline-Anna Anna, primary, De Bucourt, Maximilian, additional, Gebauer, Bernhard, additional, Amthauer, Holger, additional, Erxleben, Christoph, additional, Eucker, Jan, additional, Keller, Ulrich, additional, Leyvraz, Serge, additional, Joussen, Antonia M., additional, Keilholz, Ulrich, additional, and Ochsenreither, Sebastian, additional

Published
2022
Full Text
View/download PDF

35. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma

Author

Waguespack, Steven G, primary, Drilon, Alexander, additional, Lin, Jessica J, additional, Brose, Marcia S, additional, McDermott, Ray, additional, Almubarak, Mohammed, additional, Bauman, Jessica, additional, Casanova, Michela, additional, Krishnamurthy, Anuradha, additional, Kummar, Shivaani, additional, Leyvraz, Serge, additional, Oh, Do-Youn, additional, Park, Keunchil, additional, Sohal, Davendra, additional, Sherman, Eric, additional, Norenberg, Ricarda, additional, Silvertown, Josh D, additional, Brega, Nicoletta, additional, Hong, David S, additional, and Cabanillas, Maria E, additional

Published
2022
Full Text
View/download PDF

36. Rationale and design of ON-TRK:a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib

Author

Yang, James C.H., Brose, Marcia S., Castro, Gilberto, Kim, Edward S., Lassen, Ulrik N., Leyvraz, Serge, Pappo, Alberto, López-Ríos, Fernando, Reeves, John A., Fellous, Marc, Penault-Llorca, Frédérique, Rudzinski, Erin R., Tabatabai, Ghazaleh, Vassal, Gilles, Drilon, Alexander, Trent, Jonathan, Yang, James C.H., Brose, Marcia S., Castro, Gilberto, Kim, Edward S., Lassen, Ulrik N., Leyvraz, Serge, Pappo, Alberto, López-Ríos, Fernando, Reeves, John A., Fellous, Marc, Penault-Llorca, Frédérique, Rudzinski, Erin R., Tabatabai, Ghazaleh, Vassal, Gilles, Drilon, Alexander, and Trent, Jonathan

Abstract

Background: Tropomyosin receptor kinase (TRK) fusion proteins resulting from neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare primary oncogenic drivers in a wide array of tumors. Larotrectinib is a first-in-class, highly selective, central nervous system-active TRK inhibitor approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and over 40 countries for the treatment of TRK fusion solid tumors in adult and pediatric patients. Due to the rarity of TRK fusion cancer, larotrectinib was granted accelerated approval based on a relatively small number of patients enrolled in three early phase trials. ON-TRK aims to evaluate the safety profile of larotrectinib in a broader population and over extended time periods. Methods: ON-TRK is a prospective, non-interventional, open-label, multicenter, multi-cohort, post-approval study in adult and pediatric patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib that will describe the safety and effectiveness of larotrectinib in real-world practice conditions. Adult patients will be grouped by tumor type and followed for at least 2 years. Patients < 18 years old will be enrolled under a ‘pediatric’ cohort regardless of tumor type and will be followed for 5 years to evaluate the risk of potential long-term adverse effects of larotrectinib on their growth and development. The effectiveness of larotrectinib in the overall study population as well as in patient subgroups will also be evaluated. Procedures avoided in patients with infantile fibrosarcoma (e.g., amputation) and the number of patients who were able to undergo surgery with a curative intent (excluding amputation) because of the use of larotrectinib will be described. Larotrectinib treatment patterns in real-world practice, including dosing and duration of treatment, will be described. Discussion: The FDA Accelerated Approval Program allows for earlier approval of and patient access t

Published
2022

37. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma

Author

Waguespack, Steven G, Drilon, Alexander, Lin, Jessica J, Brose, Marcia S, McDermott, Ray, Almubarak, Mohammed, Bauman, Jessica, Casanova, Michela, Krishnamurthy, Anuradha, Kummar, Shivaani, Leyvraz, Serge, Oh, Do-Youn, Park, Keunchil, Sohal, Davendra, Sherman, Eric, Norenberg, Ricarda, Silvertown, Josh D, Brega, Nicoletta, Hong, David S, Cabanillas, Maria E, Waguespack, Steven G, Drilon, Alexander, Lin, Jessica J, Brose, Marcia S, McDermott, Ray, Almubarak, Mohammed, Bauman, Jessica, Casanova, Michela, Krishnamurthy, Anuradha, Kummar, Shivaani, Leyvraz, Serge, Oh, Do-Youn, Park, Keunchil, Sohal, Davendra, Sherman, Eric, Norenberg, Ricarda, Silvertown, Josh D, Brega, Nicoletta, Hong, David S, and Cabanillas, Maria E

Abstract

Objective: Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with demonstrated efficacy across various TRK fusion-positive solid tumours. We assessed the efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma (TC). Methods: We pooled data from three phase I/II larotrectinib clinical trials (NCT02576431, NCT02122913, and NCT02637687). The primary endpoint was the investigator-assessed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors v1.1. Secondary endpoints included duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. Data cut-off: July 2020. Results: Twenty-nine patients (median age: 60; range: 6-80) with TRK fusion-positive TC were treated. Tumour histology was papillary (PTC) in 20 (69%) patients, follicular (FTC) in 2 (7%), and anaplastic (ATC) in 7 (24%) patients. Among 28 evaluable patients, ORR was 71% (95% CI: 51-87); best responses were complete response in 2 (7%) patients, partial response in 18 (64%), stable disease in 4 (14%), progressive disease in 3 (11%), and undetermined in 1 (4%) due to clinical progression prior to the first post-baseline assessment. ORR was 86% (95% CI: 64-97) for PTC/FTC and 29% (95% CI 4-71) for ATC. Median time to response was 1.87 months (range 1.64-3.68). The 24-month DoR, PFS, and OS rates were 81, 69, and 76%, respectively. Treatment-related adverse events were mainly grades 1-2. Conclusion: In TRK fusion-positive TC, larotrectinib demonstrates rapid and durable disease control and a favourable safety profile in patients with advanced disease requiring systemic therapy. Significance statement: NTRK gene fusions are known oncogenic drivers and have been identified in various histologies of thyroid carcinoma, most commonly in papillary thyroid carcinoma. This is the first publication specifically studying a TRK inhibitor in a cohort of TRK fusion-positive thyroid carcinoma patients. In th

Published
2022

38. EORTC Melanoma Group achievements

Author

Testori, Alessandro, Suciu, Stefan, van Akkooi, Alexander C.J., Cook, Martin, Ghanem, Ghanem, Karra Gurunath, R., Keilholz, Ulrich, van Kempen, Leon, Leyvraz, Serge, Mihm, Martin, Newton-Bishop, Julia, Patel, Poulam, Robert, Caroline, Schadendorf, Dirk, de Schaetzen, Gaetan, Spatz, Alan, de Vries, Esther, and Eggermont, Alexander M.M.

Published
2012
Full Text
View/download PDF

40. 538 Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp

Author

Sacco, Joseph, primary, Carvajal, Richard, additional, Butler, Marcus, additional, Shoushtari, Alexander, additional, Hassel, Jessica, additional, Ikeguchi, Alexandra, additional, Hernandez-Aya, Leonel, additional, Nathan, Paul, additional, Hamid, Omid, additional, Piulats, Josep, additional, Rioth, Matthew, additional, Johnson, Douglas, additional, Luke, Jason, additional, Espinosa, Enrique, additional, Leyvraz, Serge, additional, Holland, Chris, additional, McCully, Michelle, additional, Abdullah, Shaad, additional, and Sato, Takami, additional

Published
2021
Full Text
View/download PDF

43. Characterization of liver function tests (LFTs) following tebentafusp (tebe) in previously treated (2L+) metastatic uveal melanoma (mUM) patients (pts).

Author

Sato, Takami, primary, Carvajal, Richard D., additional, Sacco, Joseph J., additional, Shoushtari, Alexander Noor, additional, Hassel, Jessica Cecile, additional, Ikeguchi, Alexandra, additional, Hernandez-Aya, Leonel Fernando, additional, Nathan, Paul, additional, Rioth, Matthew, additional, Hamid, Omid, additional, Piulats, Josep M., additional, Luke, Jason J., additional, Johnson, Douglas Buckner, additional, Leyvraz, Serge, additional, Espinosa, Enrique, additional, Abdullah, Shaad Essa, additional, Sum, Daniel, additional, Lockwood, Sarah, additional, Mendez, Patricia, additional, and Butler, Marcus O., additional

Published
2021
Full Text
View/download PDF

44. Long-term efficacy and safety of larotrectinib in patients with TRK fusion-positive lung cancer.

Author

Lin, Jessica Jiyeong, primary, Kummar, Shivaani, additional, Tan, Daniel Shao-Weng, additional, Lassen, Ulrik Niels, additional, Leyvraz, Serge, additional, Liu, Yongmei, additional, Moreno, Victor, additional, Patel, Jyoti D., additional, Rosen, Lee S., additional, Solomon, Benjamin Maurice, additional, Norenberg, Ricarda, additional, Dima, Laura, additional, Brega, Nicoletta, additional, Shen, Lin, additional, and Drilon, Alexander E., additional

Published
2021
Full Text
View/download PDF

45. Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM).

Author

Carvajal, Richard D., primary, Sato, Takami, additional, Butler, Marcus O., additional, Sacco, Joseph J., additional, Shoushtari, Alexander Noor, additional, Hassel, Jessica Cecile, additional, Ikeguchi, Alexandra, additional, Hernandez-Aya, Leonel Fernando, additional, Rioth, Matthew, additional, Hamid, Omid, additional, Piulats, Josep M., additional, Luke, Jason J., additional, Johnson, Douglas Buckner, additional, Leyvraz, Serge, additional, Espinosa, Enrique, additional, Collins, Laura, additional, McCully, Michelle L., additional, Lockwood, Sarah, additional, Abdullah, Shaad Essa, additional, and Nathan, Paul, additional

Published
2021
Full Text
View/download PDF

46. Uveal Melanoma - Standardised Procedure in Diagnosis, Therapy and Surveillance

Author

Bechrakis, Nikolaos E., Bornfeld, Norbert, Heindl, Ludwig M., Skoetz, Nicole, Leyvraz, Serge, Joussen, Antonia M., Bechrakis, Nikolaos E., Bornfeld, Norbert, Heindl, Ludwig M., Skoetz, Nicole, Leyvraz, Serge, and Joussen, Antonia M.

Abstract

Background Uveal melanoma is a rare intraocular tumour, for which there is currently no national evidence-based guideline in Germany. The aim of this project was to provide a common standard operating procedure (SOP) for the diagnosis, treatment and follow-up care of uveal melanoma, within the network of German leading oncology centres funded by German Cancer Aid. The SOP was created as part of a moderated consensus process. Results and Conclusion In a multistage process, a common SOP was developed for the diagnosis, therapy and follow-up of uveal melanoma, as based on current knowledge of the subject. Zusammenfassung Hintergrund Fur das uveale Melanom fehlt als seltene onkologische Erkrankung derzeit in Deutschland eine nationale evidenzbasierte Leitlinie. Bis diese erstellt wird, bietet sich eine zentrumsubergreifende Standard Operating Procedure (SOP) an. Ziel des Projektes war die Erarbeitung einer konsentierten SOP zur Diagnostik, Therapie und Nachsorge des uvealen Melanoms im Rahmen des Netzwerkes Onkologischer Spitzenzentren, die von der Deutschen Krebshilfe gefordert werden. Ergebnisse und Schlussfolgerung In einem auf dem aktuellen Wissensstand basierenden mehrstufigen Prozess eines moderierten Konsensusverfahrens konnte eine konsentierte SOP fur die Diagnostik, Therapie und Nachsorge des uvealen Melanoms erarbeitet werden.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results